Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Pentavalent antimonial (SbV) compounds
Introduction
Overview
Overview
Pentavalent antimonials (also abbreviated pentavalent Sb or SbV) are a group of compounds used for the treatment of leishmaniasis. They are also called pentavalent antimony compounds.
Types
Types
The first pentavalent antimonial used was urea stibamate: first introduced in the 1930s, it fell out of favour in the 1950s due to higher toxocity compared to sodium stibogluconate.
The compounds currently available for clinical use are:
- sodium stibogluconate (Pentostam®; manufactured by GlaxoSmithKline; available in US and UK), which is administered by slow intravenous injection.
- meglumine antimoniate (Glucantim®; manufactured by Aventis; available in Brazil, France and Italy), which is administered by intramuscular injection.
The pentavalent antimonials can only be given by injection: there are no oral preparations available.
Alternatives
Alternatives
In many countries, widespread resistance to antimony has meant that amphotericin or miltefosine are now used in preference.[1]
Side effects
Side effects
Cardiotoxity, reversible renal insufficiency, pancreatitis, anemia, leukopenia, rash, headache, abdominal pain, nausea, vomiting, arthralgia, myalgia, thrombocytopenia and transaminase elevation.
References
References
- ↑ Olliaro P, Guerin P, Gerstl S; et al. “Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004”. Lancet Infect Dis. 5 (12). doi:10.1016/S1473-3099(05)70296-6. Unknown parameter
|Pages=ignored (|pages=suggested) (help)